Published in Ann Oncol on June 13, 2012
Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. J Clin Oncol (2015) 1.49
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol (2010) 1.20
Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev (2014) 1.16
Targeting the insulin-like growth factor-1 receptor in human cancer. Front Pharmacol (2013) 1.00
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer (2013) 0.94
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91
Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol (2014) 0.90
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene (2014) 0.88
New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87
Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer (2014) 0.86
Novel agents for advanced pancreatic cancer. Oncotarget (2015) 0.86
Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood) (2015) 0.86
Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma (2014) 0.85
Impact of diabetes type II and chronic inflammation on pancreatic cancer. BMC Cancer (2015) 0.84
Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res (2013) 0.84
Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma. PLoS One (2014) 0.83
A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget (2014) 0.80
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol (Lausanne) (2015) 0.80
Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol (2014) 0.79
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Mol Cancer Ther (2013) 0.79
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. BMC Cancer (2015) 0.79
Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5. Cell Death Dis (2015) 0.77
Results on efficacy and safety of cancer treatment with or without tumor necrosis factor-related apoptosis-inducing ligand-related agents: A meta-analysis. Mol Clin Oncol (2014) 0.77
Physapubescin selectively induces apoptosis in VHL-null renal cell carcinoma cells through down-regulation of HIF-2α and inhibits tumor growth. Sci Rep (2016) 0.76
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer (2016) 0.76
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs (2015) 0.76
The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. J Cancer Res Clin Oncol (2014) 0.76
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 0.76
The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis inducing ligand. J Biol Chem (2017) 0.75
Targeted therapy in gastrointestinal malignancies. J Carcinog (2014) 0.75
Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas (2017) 0.75
Molecular therapeutics in pancreas cancer. World J Gastrointest Oncol (2016) 0.75
Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis. Nutrients (2017) 0.75
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy. Cell Death Differ (2016) 0.75
Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures. World J Gastrointest Endosc (2015) 0.75
Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma. FEBS J (2015) 0.75
Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. Int J Exp Pathol (2015) 0.75
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Med (2017) 0.75
Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. Oncol Rev (2017) 0.75
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell (1992) 9.19
Cost-effectiveness of screening for colorectal cancer in the general population. JAMA (2000) 5.88
Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA (2001) 4.30
Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst (2001) 4.26
ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet (1998) 3.66
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Rearrangement of genetic information may produce immunoglobulin diversity. Nature (1979) 2.84
Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol (2000) 2.62
Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst (2000) 2.46
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer (2009) 2.39
Calcium ions and the regulation of NAD+-linked isocitrate dehydrogenase from the mitochondria of rat heart and other tissues. Biochem J (1978) 2.38
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis (2005) 2.33
Pharmacologically effective plasma concentrations of ranitidine. Lancet (1979) 2.13
Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst (2001) 2.10
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
Screening and management of renal disease in human immunodeficiency virus-infected patients in Australia. Intern Med J (2013) 2.01
Abnormal type I collagen metabolism by cultured fibroblasts in lethal perinatal osteogenesis imperfecta. Biochem J (1984) 1.98
Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation (1994) 1.96
Technical basis for EPA's proposed regulation on the cleanup of sites contaminated with radioactivity. Health Phys (1996) 1.92
Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet (1994) 1.89
Pharmacological effects of labetalol in man. Br J Clin Pharmacol (1976) 1.86
Complex hormonal regulation of rat casein gene expression. J Biol Chem (1982) 1.80
Streptococcus iniae, a human and animal pathogen: specific identification by the chaperonin 60 gene identification method. J Clin Microbiol (1998) 1.75
Bedside emergency department ultrasonography plus radiography of the kidneys, ureters, and bladder vs intravenous pyelography in the evaluation of suspected ureteral colic. Acad Emerg Med (1998) 1.74
Relationship between plasma concentrations and pharmacological effects of labetalol. Eur J Clin Pharmacol (1977) 1.71
Body mass index and Barrett's oesophagus in women. Gut (2009) 1.70
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 1.69
Collagen II is essential for the removal of the notochord and the formation of intervertebral discs. J Cell Biol (1998) 1.69
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation (2000) 1.63
Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther (1991) 1.62
Collagen defects in lethal perinatal osteogenesis imperfecta. Biochem J (1986) 1.62
Paramedic vs private transportation of trauma patients. Effect on outcome. Arch Surg (1996) 1.61
The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol (Oxf) (2009) 1.57
Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation (2001) 1.56
Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene. Proc Natl Acad Sci U S A (1993) 1.56
Lethal perinatal osteogenesis imperfecta due to the substitution of arginine for glycine at residue 391 of the alpha 1(I) chain of type I collagen. J Biol Chem (1987) 1.54
Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol. Br J Clin Pharmacol (1976) 1.53
Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis (2014) 1.51
Prosthetic replacement of the distal femur for primary bone tumours. J Bone Joint Surg Br (1991) 1.49
Routine programmed electrical stimulation in survivors of acute myocardial infarction for prediction of spontaneous ventricular tachyarrhythmias during follow-up: results, optimal stimulation protocol and cost-effective screening. J Am Coll Cardiol (1991) 1.49
Ranitidine--a new H2-receptor antagonist. Gut (1980) 1.47
Validity of the US Behavioral Risk Factor Surveillance System's health related quality of life survey tool in a group of older Canadians. Chronic Dis Can (2001) 1.47
A base substitution at a splice site in the COL3A1 gene causes exon skipping and generates abnormal type III procollagen in a patient with Ehlers-Danlos syndrome type IV. J Biol Chem (1990) 1.47
Dietary fat and protein in relation to risk of non-Hodgkin's lymphoma among women. J Natl Cancer Inst (1999) 1.45
Implantation of a pulsatile external left ventricular assist device: role of intraoperative transesophageal echocardiography. J Cardiothorac Vasc Anesth (1994) 1.44
The six-minute walk test in healthy children: reliability and validity. Eur Respir J (2005) 1.44
The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology (1997) 1.43
Skill mix between nurses and doctors working in primary care-delegation or allocation: a review of the literature. Int J Nurs Stud (2000) 1.42
Ultrasound training for emergency physicians--a prospective study. Acad Emerg Med (2000) 1.42
Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. Br J Cancer (2009) 1.41
Deletion of 24 amino acids from the pro-alpha 1(I) chain of type I procollagen in a patient with the Ehlers-Danlos syndrome type VII. J Biol Chem (1986) 1.41
Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol (1999) 1.40
Dimensions of the human posterior septal space and coronary sinus. Am J Cardiol (1991) 1.40
The structure and genetics of mouse immunoglobulins: an analysis of NZB myeloma proteins and sets of BALB/c myeloma proteins binding particular haptens. Cold Spring Harb Symp Quant Biol (1977) 1.38
Heat exhaustion in The Sun-Herald City to Surf fun run. Med J Aust (1994) 1.38
Waist circumference and body mass index in Chinese children: cutoff values for predicting cardiovascular risk factors. Int J Obes (Lond) (2006) 1.37
Efficacy of multidisciplinary approach in treatment of constipation: a pilot study. Hong Kong Med J (2006) 1.37
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A (1996) 1.37
Malocclusion prevalence in an ethnic Chinese population. Aust Dent J (1993) 1.34
A frameshift mutation results in a truncated nonfunctional carboxyl-terminal pro alpha 1(I) propeptide of type I collagen in osteogenesis imperfecta. J Biol Chem (1989) 1.34
Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol (2004) 1.34
Identification of Enterococcus species and phenotypically similar Lactococcus and Vagococcus species by reverse checkerboard hybridization to chaperonin 60 gene sequences. J Clin Microbiol (2000) 1.34
Long-term retrograde amnesia...the crucial role of the hippocampus. Neuropsychologia (2001) 1.31
Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol (1998) 1.31
Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol (2006) 1.28
Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers Prev (2001) 1.28
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J Biol Chem (1989) 1.27
Relationship of binding of a calcium channel blocker to inhibition of contraction in intact cultured embryonic chick ventricular cells. Circ Res (1983) 1.27
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol (2013) 1.26
Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem (1994) 1.26
The effects of obesity on pulmonary function. Arch Dis Child (2003) 1.26
Collagen composition of normal and myxomatous human mitral heart valves. Biochem J (1984) 1.25
Lovastatin and rhabdomyolysis. Ann Intern Med (1988) 1.23
In vivo measurement of water diffusion in the human heart. Magn Reson Med (1994) 1.23
Double-blind trial of labetalol. Br J Clin Pharmacol (1976) 1.22
Evaluation of a computer-assisted learning programme on the oro-facial signs of child physical abuse (non-accidental injury) by general dental practitioners. Br Dent J (2001) 1.22
Substitution of arginine for glycine 664 in the collagen alpha 1(I) chain in lethal perinatal osteogenesis imperfecta. Demonstration of the peptide defect by in vitro expression of the mutant cDNA. J Biol Chem (1988) 1.21
Predicted vitamin D status and pancreatic cancer risk in two prospective cohort studies. Br J Cancer (2010) 1.19
Mannose-binding lectin and rheumatoid arthritis in southern Chinese. Arthritis Rheum (2000) 1.19
Construction and preliminary characterization of the rat casein and alpha-lactalbumin cDNA clones. J Biol Chem (1981) 1.18
Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol (1977) 1.17
Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol (1983) 1.17
Epilepsy presenting as AD: neuroimaging, electroclinical features, and response to treatment. Neurology (2002) 1.17
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol (2011) 1.16
Natural history of focal moderate cardiac allograft rejection. Is treatment warranted? Circulation (1995) 1.16
Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst (2001) 1.16
A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br J Cancer (2013) 1.15
Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology (2008) 1.12
In vitro chondrogenic differentiation of human mesenchymal stem cells in collagen microspheres: influence of cell seeding density and collagen concentration. Biomaterials (2008) 1.12
The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation 1. J Biol Chem (1996) 1.11
Multihormonal regulation of casein gene expression at the transcriptional and posttransciptional levels in the mammary gland. Recent Prog Horm Res (1980) 1.10
Preferences for treatment outcomes in patients with heart failure: symptoms versus survival. J Card Fail (2000) 1.10
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer (2001) 1.10
Screening endoscopy and risk of colorectal cancer in United States men. Cancer Causes Control (1998) 1.10
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol (2007) 1.10
Clinical pharmacology of labetalol. Br J Clin Pharmacol (1979) 1.09